Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TARABullishCorporate Developmentsnews

High materiality7/10

Protara Therapeutics advances THRIVE-3 with Phase 2b enrollment completed

Oct 15, 2026, 8:35 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone execution reduces clinical risk and sets up a data-driven catalyst in 4Q2026; biotech stocks often re-rate on clear readouts, though actual data remains a risk.

AI summary

What happened, with direct paths to the underlying reporting

Protara Therapeutics reports completion of enrollment for the THRIVE-3 Phase 2b dose confirmation study (24 patients). Interim results are slated for 4Q2026, potentially de-risking the program and serving as a near-term catalyst for TARA. Positive data could support valuation through potential treatment differentiation in intestinal failure patients dependent on parenteral support.

Completed enrollment for Phase 2b THRIVE-3 dose confirmation. 24 patients enrolled.
Interim results expected in 4Q2026 for THRIVE-3.
Company remains on track to report interim results in 4Q26.
IV Choline Chloride program targets intestinal failure patients on parenteral support.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.